Table 1 Baseline characteristics of patients with type 2 diabetes participating in clinical trials (phase 2 and 3) with the GIP/GLP-1 receptor co-agonist tirzepatide

Comparator(s)

Placebo, dulaglutide 1.5 mg

Placebo

Semaglutide 1 mg

Insulin degludec

Insulin glargine

Placebo

Study duration

Weeks

26

40

40

52

52/104*

Overall patient number

316**

478

1878

2874

1995

475

Background medication

None (monotherapy^†)

Metformin

Metformin ± SGLT-2 inhibitor

Metformin ± SGLT-2 inhibitor or sulfonylurea (alone or in combination)

Insulin glargine  ± metformin

Age

Years

57.2

54.1

56.6

57.4

63.6

60.7

Female

%

47.3

48

53

56

38

44

Duration of diabetes

years

8.7

4.7

8.6

8.4

10.5

13.3

HbA_1c

%

8.12

7.94

8.28

8.17

8.52

8.32

Fasting plasma glucose

mmol/l

9.4

8.5

9.6

9.4

9.5

9.0

Body-mass-index

kg/m²

32.5

31.9

34.2

33.5

32.6

33.4

Receiving metformin

%

90.5

–

100

100

95

82.5

Receiving SGLT-2 inhibitor

%

–

–

–

32

25

–

Receiving sulfonylurea

%

–

–

–

–

54

–

eGFR

ml/min per 1.73 m²

92.7

94.1

96.0

94.1

81.3

85.5